Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | HINT1 | P49773 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15850633 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1HPGDKDM4EADORA2A | |
| SCHEMBL14727516 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1HPGDKDM4EADORA2A | |
| SCHEMBL20215732 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1HPGDKDM4EADORA2A | |
| SCHEMBL17853311 | 0.94 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EADORA2BADORA1 | |
| SCHEMBL15892169 | 0.94 | TAS1R3 (0.44) | TAS1R3TAS1R1KDM4EADORA2BADORA1 | |
| SCHEMBL19407917 | 0.84 | TAS1R3 (0.52) | TAS1R3TAS1R1HPGDADORA2AADORA2B | |
| SCHEMBL30400675 | 0.83 | TAS1R3 (0.60) | TAS1R3TAS1R1HPGDADORA2AADORA2B | |
| SCHEMBL15841335 | 0.82 | HINT1 (0.52) | TAS1R3TAS1R1HINT1 | |
| SCHEMBL15105535 | 0.81 | TYMP (0.39) | TAS1R3TAS1R1HPGDKDM4EADORA2B | |
| SCHEMBL16002737 | 0.81 | TAS1R3 (0.43) | TAS1R3TAS1R1HPGDADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377788-B2 | Method for producing glycoside compounds | BONAC CORPORATION (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | BONAC CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377788-B2 | Method for producing glycoside compounds | TST, DIMT1, DERA | TAS1R3 1804/4885TAS1R1 2024/4885HPGD 3794/4885 |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | TST, DIMT1, DERA | TAS1R3 1804/4885TAS1R1 2024/4885HPGD 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.